Advertisement


Scott Kopetz, MD, PhD, on Metastatic Colorectal Cancer: Quality of Life Results on Encorafenib, Cetuximab, and Binimetinib

2020 Gastrointestinal Cancers Symposium

Advertisement

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the BEACON CRC trial, which had demonstrated that the triplet regimen of encorafenib, cetuximab, and binimetinib significantly improved overall survival in patients with a BRAF V600E mutation. The new analysis showed that the regimen also led to substantial improvement in patient-reported quality of life compared with current standard of care (Abstract 8).



Related Videos

Colorectal Cancer

Van K. Morris, MD, on Stage II Colon Cancer: Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy

Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses the COBRA study, which is examining circulating tumor DNA and its ability to predict whether patients with resected stage IIA colon cancer may benefit from adjuvant chemotherapy (Abstract TPS261).

Gastrointestinal Cancer

Brian M. Wolpin, MD, on Performance of a Blood-Based Test for the Detection of Multiple Cancers

Brian M. Wolpin, MD, of Dana-Farber Cancer Institute, discusses a noninvasive blood test evaluating methylation of circulating free DNA. In his study, the blood test detected multiple gastrointestinal cancers at a sensitivity of approximately 81% and a prespecified specificity of > 99%. It also accurately localized the tissue of origin across more than 20 cancer types (Abstract 283).

Pancreatic Cancer

Danielle S. Bitterman, MD, on Pancreatic Cancer: Noninvasive Genomic Profiling From Plasma ctDNA

Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97 patients with pancreatic ductal adenocarcinoma with circulating tumor DNA. Mutations were most frequently detected in patients with locally advanced and metastatic disease (Abstract 753).

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Zev A. Wainberg, MD, on PD-L1­–Positive Advanced Gastric Cancer: MSI and Combined Positive Score and Pembrolizumab vs Chemotherapy

Zev A. Wainberg, MD, of the UCLA Medical Center, discusses the first subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in PD-L1–positive disease (Abstract 427).

Hepatobiliary Cancer
Immunotherapy

Peter R. Galle, MD, on Atezolizumab/Bevacizumab vs Sorafenib for Hepatocellular Carcinoma: Patient-Reported Outcomes

Peter R. Galle, MD, of the University Medical Center, Mainz, discusses patient-reported outcomes from this phase III study, which showed the combination of atezolizumab plus bevacizumab vs sorafenib is well tolerated and may represent a new standard of care in the first-line setting for unresectable liver cancer (Abstract 476).

Advertisement

Advertisement




Advertisement